Three possible mechanisms may underlie the decrease in

Three possible mechanisms may underlie the decrease in the number of PVBs in the present patient: the first is the antiarrhythmic action of Omacor, the second is the natural time course of PVBs, and the third is the day-to-day variability in the number of PVBs. Therefore, we performed an additional evaluation in February2013. Based on the device interrogation data, which demonstrated that Merimepodib the total number of PVBs ranged from 400 to 2000 per month since March 2012 until recently, we believe that day-to-day variability of PVBs is the least likely reason for the decreased number of PVBs. Previous device testing (from June 2011 to Jan 2012) had shown up to 50,000PVBs per month. Data regarding the surrogate antiarrhythmogenic effect of PUFAs are currently rather controversial. Preliminary results from a pilot study showed that a single intravenous administration of 3.8g of omega-3 marine triglycerides resulted in decreased induction of sustained ventricular tachycardia following programmed stimulation in 5 of 7 ischemic patients with inducible ventricular tachycardia [10]. A larger study involving 98 patients with ICDs and ischemic heart disease showed that higher plasma levels of n-3-PUFAs are associated with a lower incidence of ventricular arrhythmias [11]. Several studies have shown that omega-3 fatty acids utilize multiple antiarrhythmic mechanisms, including the inhibition of calcium overload by maintenance of l-type calcium channels during cellular stress, high activity of cardiac microsomal calcium ion–magnesium ion-adenosine triphosphate synthase (Ca2+/Mg2+-ATPase), and potent inhibition of voltage-gated sodium channels [12–14].
Conclusions
Acknowledgments and funding
The development of this paper was supported by an unrestricted educational grant from Abbott Products Operations AG, Allschwil, Switzerland.